funding
funding at Beyond Market Intelligence is a file of 149 stories. The newest of them: “Neko Health raises $700 million to expand proactive body scanning”, “Oak emerges with $60M to solve AI-driven identity complexity”, and “Explore how AI unlocks new discoveries in life sciences funding”. Daniel Ek's Neko Health just closed another $700M round, and that tells you something important: proactive health is moving from niche to necessary. Oak is stepping out of stealth with $60 million in seed funding, and the timing couldn't be more telling. Acme AI is the next-generation, AI-powered spreadsheet platform built to replace Excel and redefine how analysts, data scientists, and enterprise teams work… The list below is every funding story on Beyond Market Intelligence, newest first.
Neko Health raises $700 million to expand proactive body scanning
Daniel Ek's Neko Health just closed another $700M round, and that tells you something important: proactive health is moving from niche to necessary. The startup pairs proprietary full-body scanning with bloodwork to give people a clearer read on where they stand. That's the kind of clarity traditional checkups rarely deliver. We're watching capital flow into tools that put users in control, much like the discussions coming at Disrupt 2026. If you're tracking where wellness and entrepreneurship converge, this is a space worth exploring.
Oak emerges with $60M to solve AI-driven identity complexity
Oak is stepping out of stealth with $60 million in seed funding, and the timing couldn't be more telling. As AI agents increasingly fumble through identity and access, the mess they leave behind is becoming a real liability. Shai Morag, the cofounder, knows this space well, and Oak is positioning itself to clean it up. It's a practical, needed response to a problem that's only growing.
Explore how AI unlocks new discoveries in life sciences funding
Miles Wang, an OpenAI researcher, is reportedly in talks to launch an AI-driven drug discovery startup with a $2 billion valuation. That's a striking signal of where the industry sees the next breakthrough. Investors are betting that AI can tackle the messy, high-stakes work of life sciences, not just automate spreadsheets. It's a bold move, and one that feels overdue. For anyone tracking how AI moves beyond data management into real-world impact, this is worth watching closely.
A billion-dollar bet on longevity backed by customer value, not equity.
General Catalyst's Customer Value Fund is taking a different route to back IM8, David Beckham's longevity vitamin drink startup, with a $1 billion commitment that skips equity entirely. It's a bold structure, and it signals real confidence in the brand's momentum. If you're watching how capital flows to consumer health, this is a deal worth exploring. For more on how big bets are reshaping infrastructure, check out our piece on Nscale's $3.36B raise. The pattern is clear: money is moving where the value is.
PixVerse reaches $2B valuation as 15 million users embrace AI video creation.
PixVerse has closed a $439M Series C extension, pushing its valuation past $2B on the back of 15 million monthly active users. That kind of traction signals real demand, not hype. It's easy to get lost in funding figures, but the user count is what grounds this in practical value. For anyone still wrestling with clunky video tools, this momentum suggests simpler, AI-driven workflows are worth exploring.